Investigation on the Improvement of Adverse Reactions of Paclitaxel by Nanoparticle Albumin-bound Paclitaxel and Its Clinical Status
10.13748/j.cnki.issn1007-7693.20220550
- VernacularTitle:纳米白蛋白给药系统改善紫杉醇化疗不良反应效果及其临床调查
- Author:
Xunan LI
1
;
Liying QIU
1
;
Jian YIN
2
;
Jing HU
1
Author Information
1. Jiangnan Univercity Wuxi School of Medicine
2. Jiangnan Univercity School of Biotechnology, Wuxi 214122, China
- Publication Type:Journal Article
- Keywords:
nano-albumin drug delivery system；albumin paclitaxel；adverse reactions；clinical status
- From:
Chinese Journal of Modern Applied Pharmacy
2024;41(7):962-967
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE :To investigate the clinical incidence and severity of adverse reactions related to nano-albumin-bound paclitaxel(Nab-P) and traditional solvent-based paclitaxel chemotherapy, and analyze the improvement of adverse reactions of paclitaxel treatment by nano-albumin delivery system.
METHODS
A hospital information system was used to retrospectively investigate 326 cancer patients received Nab-P chemotherapy and 303 paclitaxel chemotherapy patients who were diagnosed in the Department of Oncology of the Affiliated Hospital of Jiangnan University from July 2019 to December 2021. The information of the adverse reactions related to Nab-P and paclitaxel treatment was extracted from the electronic medical records and nursing record sheets, to explore the effect and clinical status of the nano albumin drug delivery system to improve the adverse reactions of chemotherapy.
RESULTS
Nab-P and paclitaxel-related adverse reactions such as nausea, vomiting, allergic reactions, myelosuppression, liver injury, paresthesias, phlebitis and others were significantly different in incidence and severity(P<0.05). The incidence and severity of Nab-P-related myelosuppression was higher than that of paclitaxel, while the incidence and severity of all other adverse reactions treated with Nab-P were lower.
CONCLUSION
Except for myelosuppression, Nab-P-related adverse reactions are significantly lower than traditional paclitaxel. Therefor, for patients undergoing Nab-P chemotherapy, more attention should be paid to the occurrence of myelosuppression.
